IV Levetiracetam in Epilepsy
The FDA has approved an IV formulation of levetiracetam (Keppra tablet, UCB) solution as an infusion for the adjunctive use in the treatment of partial-onset seizures in adults with epilepsy. The 100-mg/ml injection is intended as an alternative when oral administration of levetiracetam is temporarily not feasible.
When patients are switched from the oral to the IV form, the initial total daily dose should be equivalent to the total daily dosage and frequency of oral lev-etiracetam.
Levetiracetam generic should be administered as a 15-minute infusion following dilution of the dose with 100 ml of 0.9%
sodium chloride, lactated Ringer’s solution, or 5% dextrose injection. Levetir-acetam is compatible with lorazepam, diazepam, and valproate sodium injections for concomitant use.
Previously approved formulations include 250-, 500-, and 750-mg tablets and a 100-mg/ml oral solution for patients four years of age and older.
